Inhibition of cell proliferation, vascular endothelial growth factor and tumor growth by albendazole

Cancer Investigation

Volumn 27, Issue 2, 2009, Pages 171-177

  Pourgholami, Mohammad Hossein ^a   Cai, Zhao Yan ^a   Wang, Lisa ^a   Badar, Samina ^a   Links, Matthew ^a   Morris, David Lawson ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Albendazole; Angiogenesis; Microtubule; Ovarian cancer; OVCAR 3; VEGF

Indexed keywords

ALBENDAZOLE; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; ASCITES TUMOR; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ALBENDAZOLE; ANIMALS; ASCITES; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; KI-67 ANTIGEN; MICE; MICE, INBRED BALB C; OVARIAN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 60849094088     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802210752     Document Type: Article

References (40)

1. Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Disco. 2007, 6, 273-286.
2. Ferrara, N. VEGF as a therapeutic target in cancer. Oncology 2005, 69, 11-16.
3. Longo, R.; Gasparini, G. Challenges for patient selection with VEGF inhibitors. Cancer Chemother Pharmacol 2007, 60, 151-170.
4. Bates, D.O.; Harper, S.J. Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol 2002, 39, 225-237.
5. Roy, H.; Bhardwaj, S.; Yla-Herttuala, S. Biology of vascular endothelial growth factors. FEBS Lett 2006, 580, 2879-2887.
6. Shojaei, F.; Ferrara, N. Antiangiogenic therapy for cancer: An update. Cancer J 2007, 13, 345-348.
7. Boocock, C.A.; Charnock-Jones, D.S.; Sharkey, A.M.; McLaren, J.; Barker, P.J.; Wright, K.A.; Twentyman, P.R.; Smith, S.K. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995, 87, 506-516.
8. Ferrara, N.; Kerbel, R.S. Angiogenesis as a therapeutic target. Nature 2005, 438, 967-974.
9. Brustmann, H.; Naude, S. Vascular endothelial growth factor expression in serous ovarian carcinoma: Relationship with high mitotic activity and high FIGO stage. Gynecol. Oncol 2002, 84, 47-52.
10. Mesiano, S.; Ferrara, N.; Jaffe, R.B. Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization. Am J Pathol 1998, 153, 1249-1256.
11. Rad, F.H.; Le Buanec, H.; Paturance, S.; Larcier, P.; Genne, P.; Ryffel, B.; Bensussan, A.; Bizzini, B.; Gallo, R.C.; Zagury, D.; Uzan, G. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Nat Acad Sci USA 2007, 104, 2837-2842.
12. Ferrara, N.; Hillan, K.J.; Gerber, H.P.; Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Rev Drug Discovery 2004, 3, 391-400.
13. Zhong, H.; Bowen, J.P. Molecular design and clinical development of VEGFR kinase inhibitors. Curr Top Med Chem 2007, 7, 1379-1393.
14. Homsi, J.; Daud, A.I. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 2007, 14, 285-294.
15. Karashima, T.; Inoue, K.; Fukata, S.; Iiyama, T.; Kurabayashi, A.; Kawada, C.; Shuin, T. Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice. Int J Onco 2007, 30, 937-945.
16. Horton, J. Albendazole: A reviewof anthelmintic efficacy and safety in humans. Parasitology 2000, 121 Suppl, S113-132.
17. Pourgholami, M.H.; Woon, L.; Almajd, R.; Akhter, J.; Bowery, P.; Morris, D.L. In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett 2001, 165, 43-49.
18. Pourgholami, M.H.; Akhter, J.; Wang, L.; Lu, Y.; Morris, D.L. Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: In vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother & Pharmacol 2005, 55, 425-432.
19. Cachoux, F.; Isarno, T.; Wartmann, M.; Altmann, K.H. Total synthesis and biological assessment of benzimidazole-based analogues of epothilone A: Ambivalent effects on cancer cell growth inhibition. Chembiochem 2006, 7, 54-57.
20. Potashman, M.H.; Bready, J.; Coxon, A.; DeMelfi, T.M., Jr.; DiPietro, L.; Doerr, N.; Elbaum, D.; Estrada, J.; Gallant, P.; Germain, J.; Gu, Y.; Harmange, J.C.; Kaufman, S.A.; Kendall, R.; Kim, J.L.; Kumar, G.N.; Long, A.M.; Neervannan, S.; Patel, V.F.; Polverino, A.; Rose, P.; Plas, S.; Whittington, D.; Zanon, R.; Zhao, H. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. J Med. Chem 2007, 50, 4351-4373.
21. Pourgholami, M.H.; Cai, Y.Z.; Lu, Y.; Wang, L.; Morris, D.L. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin. Cancer Res. 2006, 12, 1928-1935.
22. Byrne, A.T.; Ross, L.; Holash, J.; Nakanishi, M.; Hu, L.; Hofmann, J.I.; Yancopoulos, G.D.; Jaffe, R.B. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003, 9, 5721-5728.
23. Kowanetz, M.; Ferrara, N. Vascular endothelial growth factor signaling pathways: Therapeutic perspective. Clin. Cancer Res. 2006, 12, 5018-5022.
24. Hu, L.; Zaloudek, C.; Mills, G.B.; Gray, J.; Jaffe, R.B. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000, 6, 880-886.
25. Xu, L.; Yoneda, J.; Herrera, C.; Wood, J.; Killion, J.J.; Fidler, I.J. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol 2000, 16, 445-454.
26. Holash, J.; Davis, S.; Papadopoulos, N.; Croll, S.D.; Ho, L.; Russell, M.; Boland, P.; Leidich, R.; Hylton, D.; Burova, E.; Ioffe, E.; Huang, T.; Radziejewski, C.; Bailey, K.; Fandl, J.P.; Daly, T.; Wiegand, S.J.; Yancopoulos, G.D.; Rudge, J.S. VEGF-Trap:A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002, 99, 11393-11398.
27. Liang, W.C.; Wu, X.; Peale, F.V.; Lee, C.V.; Meng, Y.G.; Gutierrez, J.; Fu, L.; Malik, A.K.; Gerber, H.P.; Ferrara, N.; Fuh, G. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF J Biol Chem 2006, 281, 951-961.
28. Carmeliet, P.; Jain, R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257.
29. Fukumura, D.; Xavier, R.; Sugiura, T.; Chen, Y.; Park, E.C.; Lu, N.; Selig, M.; Nielsen, G.; Taksir, T.; Jain, R.K.; Seed, B. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998, 94, 715-725.
30. Guichard, S.; Montazeri, A.; Chatelut, E.; Hennebelle, I.; Bugat, R.; Canal, P. Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: Pharmacokinetic and pharmacodynamic evaluation. Clin Cancer Res 2001, 7, 3222-3228.
31. Hu, L.; Hofmann, J.; Zaloudek, C.; Ferrara, N.; Hamilton, T.; Jaffe, R.B. Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002, 161, 1917-1924.
32. Hu, Y.L.; Albanese, C.; Pestell, R.G.; Jaffe, R.B. Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells. J Natl Cancer Inst 2003, 95, 733-740.
33. McCormick, D.; Chong, H.; Hobbs, C.; Datta, C.; Hall, P.A. Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathology 1993, 22, 355-360.
34. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J.T.; Bokesch, H.; Kenney, S.; Boyd, M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990, 82, 1107-1112.
35. Jalava, P.; Kuopio, T.; Juntti-Patinen, L.; Kotkansalo, T.; Kronqvist, P.; Collan, Y. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: Proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 2006, 48, 674-682.
36. Goff, B.A.; Ries, J.A.; Els, L.P.; Coltrera, M.D.; Gown, A.M. Immunophenotype of ovarian cancer as predictor of clinical outcome: Evaluation at primary surgery and second-look procedure. Gynecol Oncol 1998, 70, 378-385.
37. Hasumi, Y.; Mizukami, H.; Urabe, M.; Kohno, T.; Takeuchi, K.; Kume, A.; Momoeda, M.; Yoshikawa, H.; Tsuruo, T.; Shibuya, M.; Taketani, Y.; Ozawa, K. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res 2002, 62, 2019-2023.
38. Barbera-Guillem, E.; Nyhus, J.K.; Wolford, C.C.; Friece, C.R.; Sampsel, J.W. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res 2002, 62, 7042-7049.
39. Osusky, K.L.; Hallahan, D.E.; Fu, A.; Ye, F.; Shyr, Y.; Geng, L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004, 7, 225-233.
40. Hu, L.; Hofmann, J.; Jaffe, R.B. Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma. Clin Cancer Res 2005, 11, 8208-8212.